Jim Tananbaum Contribution to the Development of Next-Gen Clinical Drugs

On 24th April 2017, Foresite Capital made a press statement and announced the addition of Dr. Molly He to their family. Dr. He became a venture partner in the institution. She held the post of director at Illumina before moving to Foresite Capital. The company is set to benefit from her 15 years’ experience in pharmaceutical and genomic research development. The managing director in Foresite, Jim Tananbaum stated that Dr. He is among the most respected scientific researchers. She has expertise in the next generation sequencing. Additionally, he said that the new addition would enable the institution to expand and diversify its portfolios. Dr. He has an exemplary leadership track record, experience in genomics and drug development. Check out his LinkedIn account for details.

At her previous position at Illumina, she got tasked with overseeing and leading the company’s global reagent innovation and improvements. She was also in charge of protein sciences at Pacific Biosciences. At this company, she was responsible for protein reagent development. Before venturing into the field of research development, Dr. He spent 10 years in the pharmaceutical industry. During this time, she focused on the structural design of antibody and the development of drugs to suppress cancer and immune diseases. She is a graduate of Nankai University and a Ph.D. holder from the University of California. Her Doctor of Philosophy has enabled her to publish over 20 papers and patent over 20 next generation sequencing and personalized medicine.

Foresite also invests in innovative companies in the healthcare sector. Dr. He said that she was honored to join a seasoned and dynamic team. She was pleased to be part of advancements that had the potential to fuel breakthroughs in the clinical and drug development industry.

Jim Tananbaum is the man behind Foresite Capital. He got tasked with making the critical decisions that propel the company towards achieving clinical and drug breakthroughs. In the span of his career, he has managed investments in over 21 institutions. Before joining Foresite, Tananbaum held management positions at Gel Tex and Theravance. More details can be found on his Crunchbase profile.

Jim Tananbaum is a graduate of Harvard Medical School and has an M.B.A from the School of Business at Harvard. Additionally, he holds a Bachelor of Science and B.S.E.E. from Yale University. He has made it to the Midas list and has specialties in genetic epidemiology, clinical pharmacology .and clinical immunology.

Check out his Facebook page

Read more: http://pelotontherapeutics.com/bod-jim-tananbaum/